# Differential modulation of haematopoietic and oxidative injury by PARP-1 and ATR kinase inhibition in a murine model of acute irradiation

**Authors:** Baydaa Taher Sih, Hesham M.H. Zakaly, Hesham M.H. Zakaly, Hesham M.H. Zakaly, Hesham M.H. Zakaly

PMC · DOI: 10.1371/journal.pone.0344101 · 2026-03-06

## TL;DR

This study shows that giving PARP inhibitors after radiation exposure helps protect mice from blood and oxidative damage, while ATR inhibitors do not.

## Contribution

The study demonstrates the differential protective effects of post-exposure PARP-1 and ATR kinase inhibition in acute radiation injury.

## Key findings

- PARP inhibition after radiation reduced anemia and white blood cell loss in mice.
- PARP inhibitors increased antioxidant activity and reduced DNA damage.
- ATR kinase inhibitors showed no protective effects after radiation exposure.

## Abstract

Temporal Modulation of Acute Radiation Injury by Post-Exposure PARP-1 versus ATR Kinase Inhibition.

PARP-1 and ATR inhibitors have been employed as radiosensitizers in cancer therapy. In addition to this, there is little evidence about the role of these chemicals after a dose of radiation, specifically in relation to reducing damage to healthy cells rather than increasing it.

The goal of this study was to determine if PARP-1 or ATR kinase inhibitors, when delayed administered, could decrease the severity of the condition caused by an acute dose of radiation and compare the impact of PARP-1 and ATR inhibitors.

Mice of the C57BL/6 strain were subjected to a total body irradiation dose of 2.5 Gy γ-rays. In each experiment, thirty minutes following exposure to IR, either the PARP inhibitor, olaparib at 50 mg/kg or the ATR kinase inhibitor VE-821 at 25 mg/kg was injected intraperitoneally into the mice. The parameters of blood were measured at the same time as oxidative stress, including the activity of superoxide dismutase and levels of malondialdehyde. Examination of DNA damage and repair dynamics was done through the use of γ-H2AX immunofluorescence.

Following exposure to ionising radiation, mice which had received a PARP inhibitor showed less marked haemoglobin reduction and less radiation-induced leucopenia than control mice exposed to radiation alone. The modifications were accompanied by a decrease in lipid peroxidation plus enhanced antioxidant activity. This observation that PARP inhibition enhances repair of DNA double-strand breaks is consistent with earlier data from other researchers. In contrast the protective effects of the ATR kinase inhibitor were not apparent when administered after the DNA damage had been inflicted in any of the parameters examined.

While administering PARP inhibitors following the exposure to ionising radiation was found to reduce the severity of the condition experienced by the subject, as a result of acute radiation syndrome, the same was not seen when the treatment with ATR inhibitors was given to affected subjects. The results of this study show the significance of administering therapeutic agents at the right time to stop the injury to normal cells when DNA repair pathways are activated by exposure to ionising radiation.

## Linked entities

- **Proteins:** PARP1 (poly(ADP-ribose) polymerase 1)
- **Chemicals:** olaparib (PubChem CID 23725625), VE-821 (PubChem CID 51000408)
- **Diseases:** acute radiation syndrome (MONDO:0033938)

## Full-text entities

- **Genes:** Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, Parp1 (poly (ADP-ribose) polymerase family, member 1) [NCBI Gene 11545] {aka 5830444G22Rik, ARTD1, Adprp, Adprt1, PARP, PPOL}, Atr (ataxia telangiectasia and Rad3 related) [NCBI Gene 245000], Trp53bp1 (transformation related protein 53 binding protein 1) [NCBI Gene 27223] {aka 53BP1, Tp53bp1, m53BP1, p53BP1}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, Rad51 (RAD51 recombinase) [NCBI Gene 19361] {aka Rad51a, Reca}, H2ax (H2A.X variant histone) [NCBI Gene 15270] {aka H2A.X, H2afx, Hist5-2ax, gammaH2ax}, Epo (erythropoietin) [NCBI Gene 13856], Chek1 (checkpoint kinase 1) [NCBI Gene 12649] {aka Chk1, rad27}, Afg3l2 (AFG3-like AAA ATPase 2) [NCBI Gene 69597] {aka 2310036I02Rik, Emv66, par}
- **Diseases:** DNA Damage (MESH:D004266), blood vessel damage (MESH:D009383), leukopenia (MESH:D007970), metabolic dysfunction (MESH:D008659), mitochondrial damage (MESH:D028361), fibrosis (MESH:D005355), IR (MESH:C537629), inflammatory (MESH:D007249), leucopenia (MESH:C536227), cancer (MESH:D009369), loss of consciousness (MESH:D014474), anaemia (MESH:D000743), leukaemia (MESH:D015458), acute radiation syndrome (MESH:D054508), Radiation Injury (MESH:D011832), necrosis (MESH:D009336), BRCA-deficient (MESH:D001941), dislocation (MESH:D004204), hematological toxicity (MESH:D006402), brain toxicity (MESH:D001927), anemia (MESH:D000740), weight loss (MESH:D015431), toxicity (MESH:D064420), bone marrow damage (MESH:D001855)
- **Chemicals:** isoflurane (MESH:D007530), PMMA (MESH:D019904), water (MESH:D014867), hydroxyl radical (MESH:D017665), paraffin (MESH:D010232), lipid peroxide (MESH:D008054), xylazine (MESH:D014991), Olaparib (MESH:C531550), ATRi (MESH:C069225), VE 821 (MESH:C560580), lipid (MESH:D008055), ATP (MESH:D000255), Evans Blue (MESH:D005070), ROS (MESH:D017382), DMSO (MESH:D004121), DAPI (MESH:C007293), TBARS (MESH:D017392), NAD (MESH:D009243), PBS (MESH:D007854), 59Fe (MESH:C000615388), polyunsaturated fatty acids (MESH:D005231), 137Cs Gamma Cell 3000 (-), amifostine (MESH:D004999), MDA (MESH:D008315)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Figures

28 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965550/full.md

---
Source: https://tomesphere.com/paper/PMC12965550